Positive Efficacy Data in Murdoch Children’s Research Institute Urinary Tract Infection Animal Study
Highlights:
Murdoch Children’s Research Institutedata shows significant RECCE®327 (R327)
bactericidal activity againstEscherichia coliUrinary Tract Infections (UTI) in rat
model via intravenous infusion and new direct-to-bladder delivery
R327 is currently undergoing a Phase I/II UTI/Urosepsis Rapid Infusion Clinical
Trial to address needs at first patient presentation in GP and hospital settings
In 2019, >404.6m individualshad UTI’sglobally, ~80% resistant to two or more
antibiotics
Results of UTI study support potential for present Phase I/II Clinical Trial
Good results coming for patients - great to see
Ann: Murdoch Children's R327 Efficacy UTI in-vivo, page-2
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
58.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $118.3M | |||
| Open | High | Low | Value | Volume |
| 58.5¢ | 59.5¢ | 58.0¢ | $5.948K | 10.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 17433 | 58.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 23/05/2024 (20 minute delay) ? |
|
|||||
|
Last
58.0¢ |
Change
0.000 ( 1.88 %) |
||||
| Open | High | Low | Volume | ||
| 58.5¢ | 60.0¢ | 58.0¢ | 3888 | ||
| Last updated 15.03pm 23/05/2024 ? | |||||
| RCE (ASX) Chart |